Onesource Specialty Pharma Limited has informed the Exchange regarding a press release dated May 13, 2026, titled "OneSource Announces FY26 Results with Strong Q4 Performance;Reaffirms FY28 Guidance".
Press Release May 13 2026
Filed with NSE · · 26 pages · English
Summary by 6ix AI
The company reaffirmed its guidance for future revenue and EBITDA margins, indicating confidence in continued growth supported by recent approvals and market expansions. Overall, the results reflect a recovery from previous challenges, with a focus on expanding capabilities and maintaining compliance across its operations.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
OneSource Specialty Pharma Limited on 6ix
In the deck
Earlier from OneSource Specialty Pharma
- Press Release May 04 2026
- Press Release Apr 29 2026
- Press Release Apr 21 2026
- Press Release Feb 11 2026
- Press Release Nov 11 2025
Later from OneSource Specialty Pharma
- Onesource Specialty Pharma Limited Press Release Jul 24 2026
- Onesource Specialty Pharma Limited has informed the Exchange regarding a press release dated October 27, 2026, titled "OneSource Announces Strong Q2FY27 ResultsRevenue up 37% YoY and EBITDA up 53% YoY".
- Onesource Specialty Pharma Limited has informed the Exchange regarding a press release dated October 30, 2026, titled "OneSource Receives USFDA EIR with VAI Classification, Marking Completion of Inspection Process at its Sterile Product Division (SPD) Facility in Bengaluru".
Follow OneSource Specialty Pharma into a list and get an email when it puts out news.
Follow OneSource Specialty Pharma